On the basis of the available evidence from subgroup analyses of clinical studies and retrospective studies, the efficacy of anti-PD-1/PD-L1 therapy in patients with NSCLC and liver metastases remains controversial. Here, PDCD1 is linked to non-small cell lung carcinoma.